- Home
- PHUN vs MDXH Comparison
PHUN vs MDXH Comparison
Compare PHUN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHUN | MDXH |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 183.4M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PHUN | MDXH |
|---|---|---|
| Price | $1.72 | $3.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.25 | ★ $7.67 |
| AVG Volume (30 Days) | 98.6K | ★ 108.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,883,000.00 | N/A |
| Revenue This Year | N/A | $30.31 |
| Revenue Next Year | $95.95 | $18.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $1.36 |
| 52 Week High | $3.88 | $5.33 |
Technical Indicators
Market Signals| Indicator | PHUN | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 40.51 |
| Support Level | $1.60 | $3.05 |
| Resistance Level | $2.04 | $3.78 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 54.55 | 7.34 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.